Business & Finance
CRH Medical posts higher revenues of USD100.24m for 2017
6 March 2018 -

Gastrointestinal treatment company CRH Medical Corporation (TSX:CRH) (NYSE MKT:CRHM) stated on Monday that its revenues amounted to USD100.24m for the full fiscal year ended 31 December 2017.

This marks an improvement when compared over revenues of USD78.355m for the year ended 31 December 2016.

The company said the increase in revenue is mainly attributable to revenue contributions from the anesthesia businesses acquired in 2017, along with acquisitions completed mid-year in fiscal 2016.

Adjusted operating EBITDA of USD34.336m was announced for the year ended 31 December 2017 , a rise of USD1.965m from the year ended 31 December 2016, which is a reflection of the contributions from acquisitions completed in 2017, offset by the negative revenue rate and payor mix variances recorded.

Total adjusted operating expenses of USD51.108m for the year ended 31 December 2017, an increase versus USD36.864m for the year ended 31 December 2016.